Huma Partners with Merck KGaA to Develops Cancer Treatment

Huma Therapeutics (Huma) and Merck KGaA, Darmstadt, Germany has collaborated to create a digital solution with the goal of assisting cancer patients in comprehending and handling their conditions and treatment. Huma, a prominent digital health company, has partnered with Merck KGaA, a renowned science and technology company, in this venture. Patients receiving cancer therapies by Merck KGaA, Darmstadt, Germany will have access to the Cross-Indication Disease Management Platform.The preliminary direct-to-patient solution is planned to launch in 2024, specifically aimed at supporting urothelial carcinoma patients in the UK.By implementing Huma's disease-agnostic Software as a Medical Device (SaMD) technology platform, which stands as the first of its kind to attain both EU MDR Class IIb regulation and FDA Class 2 510(k) clearance, Huma and Merck KGaA, Darmstadt, Germany are aiming to enhance patient comprehension of their condition and treatment plans , promoting adherence to prescribed therapies. Additionally, the collaboration seeks to facilitate dialogue between patients and their healthcare providers, provide timely educational materials, and foster a supportive community network by enabling connections between patients and caregivers.In reference to Huma, Dan Vahdat, the esteemed CEO and founder, emphasized their unwavering commitment to pushing the boundaries of digital-first care and research. The partnership we have established with Merck KGaA, Darmstadt, Germany, represents a significant milestone in our efforts to enhance the effectiveness of patient care , both on an individual and a systemic scale. We have made significant advancements in regulations, allowing us to introduce advanced digital companion apps and AI algorithms that can assist patients and healthcare professionals effectively. We are ecstatic to announce our collaboration with Merck KGaA, Darmstadt, Germany, to embark on this ambitious venture in the field of oncology.